Engitix’s mission is to identify more relevant drug targets and effective therapeutics for fibrosis and solid tumors by testing cells in their natural microenvironment using the company’s pioneering human extracellular matrix platform. The use of more physiologically relevant human in vitro models is transforming our ability to identify new targets, determine mechanisms of action, and more accurately predict the efficacy of therapeutics candidates. Engitix is headquartered at the Royal Free Hospital, London.
- Steve Arlington, PhD Chairman
- Giuseppe Mazza, PhD Co-founder & CEO
- Gino Van Heeke, PhD CSO